Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NYSE:HIMS NYSE:PACS NASDAQ:PGNY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$131.09-0.8%$119.52$10.26▼$151.02$6.45B0.091.25 million shs640,879 shsHIMSHims & Hers Health$22.47+0.8%$24.05$13.74▼$70.43$5.08B2.4328.94 million shs27.30 million shsPACSPACS Group$36.82+0.0%$34.38$7.50▼$43.08$5.83B-0.03939,341 shs951,411 shsPGNYProgyny$24.60+2.3%$18.63$16.10▼$28.75$1.88B0.911.68 million shs2.16 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity-0.82%+5.14%+7.05%+24.01%+1,126.29%HIMSHims & Hers Health+0.95%-10.24%-21.83%+41.96%-63.97%PACSPACS Group+0.04%-10.29%+4.72%-5.59%+245.74%PGNYProgyny+2.29%+4.90%+35.76%+20.83%+14.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$131.09-0.8%$119.52$10.26▼$151.02$6.45B0.091.25 million shs640,879 shsHIMSHims & Hers Health$22.47+0.8%$24.05$13.74▼$70.43$5.08B2.4328.94 million shs27.30 million shsPACSPACS Group$36.82+0.0%$34.38$7.50▼$43.08$5.83B-0.03939,341 shs951,411 shsPGNYProgyny$24.60+2.3%$18.63$16.10▼$28.75$1.88B0.911.68 million shs2.16 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity-0.82%+5.14%+7.05%+24.01%+1,126.29%HIMSHims & Hers Health+0.95%-10.24%-21.83%+41.96%-63.97%PACSPACS Group+0.04%-10.29%+4.72%-5.59%+245.74%PGNYProgyny+2.29%+4.90%+35.76%+20.83%+14.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$149.3013.89% UpsideHIMSHims & Hers Health 2.12Hold$29.3730.72% UpsidePACSPACS Group 2.71Moderate Buy$48.0030.36% UpsidePGNYProgyny 2.92Moderate Buy$29.5520.10% UpsideCurrent Analyst Ratings BreakdownLatest PGNY, CELC, PACS, and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026PGNYProgyny Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$19.00 ➝ $30.005/19/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $28.005/18/2026PACSPACS Group Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $52.005/18/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.005/15/2026PGNYProgyny BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.005/15/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$150.00 ➝ $183.005/15/2026CELCCelcuity Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$157.005/14/2026PACSPACS Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026PACSPACS Group OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $48.005/13/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $30.005/12/2026HIMSHims & Hers Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$1.10 per shareN/AHIMSHims & Hers Health$2.35B2.18$0.84 per share26.63$1.96 per share11.46PACSPACS Group$5.29B1.10$1.60 per share23.03$6.58 per share5.60PGNYProgyny$1.29B1.50$0.75 per share32.67$5.61 per share4.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A2,184.83N/AN/A-244.61%-50.22%N/AHIMSHims & Hers Health$128.37M-$0.09N/A45.8539.32-0.56%6.10%1.52%N/APACSPACS Group$191.54M$1.5623.6015.091.124.49%26.47%4.36%N/APGNYProgyny$58.52M$0.7731.9518.641.285.23%13.34%9.03%8/6/2026 (Estimated)Latest PGNY, CELC, PACS, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/11/2026Q1 2026PACSPACS Group$0.42$0.50+$0.08$0.50$1.36 billion$1.42 billion5/7/2026Q1 2026PGNYProgyny$0.2560$0.29+$0.0340$0.29$326.47 million$328.50 million3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/A2/26/2026Q4 2025PGNYProgyny$0.38$0.48+$0.10$0.14$314.26 million$318.40 million2/23/2026Q4 2025HIMSHims & Hers Health$0.02$0.08+$0.06$0.08$619.48 million$617.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31HIMSHims & Hers Health2.181.691.56PACSPACS Group0.270.990.99PGNYProgynyN/A2.132.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%HIMSHims & Hers Health63.52%PACSPACS GroupN/APGNYProgyny94.93%Insider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%HIMSHims & Hers Health11.76%PACSPACS Group70.10%PGNYProgyny9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionableHIMSHims & Hers Health2,442227.94 million201.13 millionOptionablePACSPACS Group47,455158.27 million47.32 millionOptionablePGNYProgyny31078.33 million70.58 millionOptionablePGNY, CELC, PACS, and HIMS HeadlinesRecent News About These CompaniesProgyny, Inc. (NASDAQ:PGNY) Receives Average Rating of "Moderate Buy" from AnalystsMay 19 at 2:22 AM | americanbankingnews.comProgyny and Standex International have been highlighted as Zacks Bull and Bear of the DayMay 18 at 12:10 PM | sharewise.comSBull of the Day: Progyny (PGNY)May 18 at 5:01 AM | zacks.comProgyny, Inc. $PGNY Shares Sold by Thrivent Financial for LutheransMay 17 at 5:31 AM | marketbeat.comShareholders Will Be Pleased With The Quality of Progyny's (NASDAQ:PGNY) EarningsMay 16, 2026 | finance.yahoo.comProgyny, Inc. $PGNY Shares Bought by First Eagle Investment Management LLCMay 14, 2026 | marketbeat.com151,931 Shares in Progyny, Inc. $PGNY Purchased by Simcoe Capital LLCMay 13, 2026 | marketbeat.comCritical Review: Progyny (NASDAQ:PGNY) & Solventum (NYSE:SOLV)May 13, 2026 | americanbankingnews.comProgyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comProgyny (NASDAQ:PGNY) Given New $31.00 Price Target at Citizens JmpMay 12, 2026 | americanbankingnews.comProgyny (NASDAQ:PGNY) Given New $30.00 Price Target at Truist FinancialMay 12, 2026 | americanbankingnews.com3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNYMay 11, 2026 | zacks.comA Look At Progyny (PGNY) Valuation After Raised Guidance And Share RepurchaseMay 11, 2026 | finance.yahoo.comProgyny (NASDAQ:PGNY) Stock Price Expected to Rise, Truist Financial Analyst SaysMay 11, 2026 | marketbeat.comProgyny, Inc. to Present at BofA Securities 2026 Health Care ConferenceMay 11, 2026 | globenewswire.comCitizens Jmp Forecasts Strong Price Appreciation for Progyny (NASDAQ:PGNY) StockMay 11, 2026 | marketbeat.comVanguard Group Inc. Has $247.39 Million Holdings in Progyny, Inc. $PGNYMay 9, 2026 | marketbeat.comProgyny (NASDAQ:PGNY) Raised to Strong-Buy at Zacks ResearchMay 9, 2026 | marketbeat.comProgyny, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comProgyny surges 19% on strong earnings beatMay 8, 2026 | investing.comWhy is Progyny (PGNY) stock soaring todayMay 8, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026PGNY, CELC, PACS, and HIMS Company DescriptionsCelcuity NASDAQ:CELC$131.09 -1.09 (-0.82%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$132.57 +1.48 (+1.13%) As of 05/19/2026 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Hims & Hers Health NYSE:HIMS$22.46 +0.18 (+0.79%) Closing price 05/19/2026 03:59 PM EasternExtended Trading$22.42 -0.04 (-0.18%) As of 05/19/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.PACS Group NYSE:PACS$36.82 +0.01 (+0.03%) Closing price 05/19/2026 03:59 PM EasternExtended Trading$36.49 -0.33 (-0.89%) As of 05/19/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Progyny NASDAQ:PGNY$24.60 +0.55 (+2.29%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$24.84 +0.24 (+0.98%) As of 05/19/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
